Interferon-free, direct-acting antiviral therapy for chronic hepatitis C

Julio A. Gutierrez, E. J. Lawitz, F. Poordad

Research output: Contribution to journalReview articlepeer-review

72 Scopus citations


The treatment environment for chronic hepatitis C has undergone a revolution, particularly in genotype 1. Gone are interferon-based therapy and its associated tolerability challenges, inadequate response rates and numerous baseline factors that affect response to therapy. New and emerging treatment regimens employ all-oral combinations of direct-acting antiviral agents, and results of clinical trials suggest that these regimens routinely achieve cure rates >90%, even in patients who failed prior interferon-based triple therapy. In 2015, three all-oral FDA-approved regiments will be available for genotype 1 (sofosbuvir /ledipasvir, sofosbuvir/simeprevir, and paritaprevir/r/ombitasvir/dasabuvir). Furthermore, new treatment combinations appear to be more tolerable and require shorter duration of therapy. We provide an overview of the classes of direct-acting antiviral agents (DAAs), the clinical factors affecting their integration into combination therapies and recent findings from trials of such combination therapies in patients with genotype 1 HCV infection.

Original languageEnglish (US)
Pages (from-to)861-870
Number of pages10
JournalJournal of Viral Hepatitis
Issue number11
StatePublished - Nov 2015


  • GS-9669
  • NS5A inhibitor
  • RNA polymerase inhibitor
  • asunaprevir
  • beclabuvir
  • daclatasvir
  • dasabuvir
  • direct-acting antivirals
  • elbasvir
  • faldaprevir
  • genotype 1
  • grazoprevir
  • hepatitis C
  • ledipasvir
  • ombitasvir
  • paritaprevir
  • protease inhibitor
  • resistance-associated variants
  • ribavirin
  • simeprevir
  • sofosbuvir

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology
  • Hepatology


Dive into the research topics of 'Interferon-free, direct-acting antiviral therapy for chronic hepatitis C'. Together they form a unique fingerprint.

Cite this